In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

Vial Stopper Compatibility: Criteria and Testing Methods
Publications, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations

Derisking the Development of Sensitive Injectables
Webinars, Pharmaceutical, Drug Delivery Innovations, Market Insights, Product Solutions

Helping Pharma Manufacturers Meet New Annex 1 Requirements
Publications, Pharmaceutical, Market Insights, Product Solutions

Advanced Parenteral Closure Solutions: The Perfect Fit Towards Compliance with EMA GM...
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions